Novo Nordisk reduces the price of Ozempic by half to $ 499 for eligible and re -eligible American patients

Details of lower prices

• Who benefits? The reduced price applies to self -pending patients – those without insurance or whose insurance does not cover ozempic. More than 70,000 American pharmacies participate thanks to partnerships with Goodrx and Novocare, the Novo Nordisk cash register.
• What is the new price? $ 499 per month for Ozempic (all forces), compared to the previous list of $ 997. Wegovy, another NOVO semaglutide -based drug, is also available at this price for cash buyers.
• How to access the offer? Eligible patients can obtain an ozempic at a reduced price by paying their pocket in participating pharmacies or ordering online with home delivery via Novocare or Goodrx.

Justification behind the November

Novo Nordisk said that the decision was part of a continuous effort to make authentic semaglutid drugs approved by the FDA more accessible, in particular to those who could otherwise turn to unwelling and aggravated alternatives. The company has stressed that affordability is not only a response to competitive market pressures, including the continuous expansion of Eli Lilly in diabetes and obesity treatments, but also a direct effort to prioritize patient safety and access.

“Improvement of access to our authentic treatments approved by the FDA is at the heart of our Novo Nordisk mission,” said Dave Moore, executive vice-president, US operations of Novo Nordisk. “Although Ozempic is well covered in the United States, let’s not forget that there are patients who pay instead for this vital medication. We think that even a single patient feels the need to turn to potentially dangerous and not approved alternatives, it is too large.”

After the announcement, Novo Nordisk’s shares jumped almost 5% while Goodrx jumped almost 40%. Analysts consider the drop in price as a proactive response to rival drug launches and a continuous political examination on high American drug prices.

To be clear, most diabetic patients insured in the United States are already paying much less than the full price of the list for Ozempic – generally, it is just under $ 25 per month. However, the new program is specifically targeted against uninsured or under-assured people who have faced the highest costs. Price reduction also occurs shortly after Wegovy has received approval from the FDA for new treatment with liver disease, expanding its indications and market scope.

For this story, Fortune Used a generative AI to help an initial project. An editor checked the accuracy of the information before the publication.